Loading…

End-of-Life Care for Older Adults with Aggressive Non-Hodgkin Lymphoma

Background: Aggressive non-Hodgkin lymphoma (NHL) commonly affects older adults and is often treated with intensive therapies. Receipt of intensive therapies and absence of a clear transition between the curative and palliative phases of treatment yield prognostic uncertainty and risk for poor end-o...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2021-11, Vol.138 (Supplement 1), p.5005-5005
Main Authors: Markovitz, Netana H., Yi, Alisha, Odejide, Oreofe O., Newcomb, Richard, Amonoo, Hermioni L., Nelson, Ashley M., Reynolds, Matthew J., Rice, Julia, Lavoie, Mitchell W., Nipp, Ryan D., El-Jawahri, Areej, Johnson, Patrick Connor Connor
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 5005
container_issue Supplement 1
container_start_page 5005
container_title Blood
container_volume 138
creator Markovitz, Netana H.
Yi, Alisha
Odejide, Oreofe O.
Newcomb, Richard
Amonoo, Hermioni L.
Nelson, Ashley M.
Reynolds, Matthew J.
Rice, Julia
Lavoie, Mitchell W.
Nipp, Ryan D.
El-Jawahri, Areej
Johnson, Patrick Connor Connor
description Background: Aggressive non-Hodgkin lymphoma (NHL) commonly affects older adults and is often treated with intensive therapies. Receipt of intensive therapies and absence of a clear transition between the curative and palliative phases of treatment yield prognostic uncertainty and risk for poor end-of-life (EOL) outcomes. However, data regarding the EOL outcomes of this population are lacking. Methods: We conducted a retrospective analysis of adults >65 years with aggressive NHL treated with systemic therapy at Massachusetts General Hospital from 4/2000-7/2020 who subsequently died. We abstracted patient and clinical characteristics and EOL outcomes from the electronic health record (EHR), including patients' place of death, cause of death, palliative care and hospice utilization, and hospice length of stay using the EHR and the Social Security Death Index. We also determined whether patients were hospitalized (yes versus no), received systemic therapy (yes versus no), or were admitted to the ICU (yes versus no) within 30 days of death. Using multivariable logistic regression, we examined factors associated with hospitalization within 30 days of death and hospice utilization. Results: Among 91 patients (median age = 75 years; 37.4% female), the most common lymphoma diagnosis was de novo DLBCL/grade 3B follicular lymphoma (64/91, 70.3%), and the majority (64/91, 70.3%) had advanced stage disease. Overall, 70.3% (64/91) were hospitalized, 34.1% (31/91) received systemic therapy, and 23.3% (21/90) had an intensive care unit admission within 30 days of death. The rates of palliative care consultation and hospice utilization were 47.7% (42/88) and 39.8% (35/88), respectively. A minority (21/88, 23.9%,) received palliative care more than 30 days before death. Of those receiving palliative care consultations, the majority (33/42, 78.6%) occurred exclusively in the inpatient setting, and most (32/42, 76.2%) were seen either as a one-time consultation or followed during a single inpatient hospitalization. Symptom management (24/42, 57.1%) was the most common reason for palliative care consultation, followed by both symptom management and goals of care (11/42, 26.2%) and goals of care (4/42, 9.5%). Only 39.8% (35/88) received hospice services, with 80.7% (71/88) having a hospice length of stay ≤ 7 days. Among hospice enrollees, the median length of stay on hospice was 7 days (range: 0-117). Among all patients, 51.6% (47/91) died in hospital, rehab, or nursing home, 2
doi_str_mv 10.1182/blood-2021-146527
format article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2021_146527</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000649712106897X</els_id><sourcerecordid>S000649712106897X</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1377-49c360e0b4dd75f35e6d8598812b0a38c9e17f5c7104c280386f95431b36fa843</originalsourceid><addsrcrecordid>eNp9kM1OAjEURhujiYg-gLu-QPXedjrTiStCQEwmstF1M9MfqA5T0iKGtxfEtatvdb6cHELuER4QFX_s-hgt48CRYVFKXl2QEUquGACHSzICgJIVdYXX5CbnDwAsBJcjMp8NlkXPmuAdnbbJUR8TXfbWJTqxX_0u0--wW9PJapVczmHv6Gsc2CLa1WcYaHPYbNdx096SK9_22d397Zi8z2dv0wVrls8v00nDDIqqOgoYUYKDrrC2kl5IV1ola6WQd9AKZWqHlZemQigMVyBU6WtZCOxE6VtViDHB869JMefkvN6msGnTQSPoUwj9G0KfQuhziCPzdGbcUWwfXNLZBDcYZ0NyZqdtDP_QPy0eZCM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>End-of-Life Care for Older Adults with Aggressive Non-Hodgkin Lymphoma</title><source>ScienceDirect Additional Titles</source><creator>Markovitz, Netana H. ; Yi, Alisha ; Odejide, Oreofe O. ; Newcomb, Richard ; Amonoo, Hermioni L. ; Nelson, Ashley M. ; Reynolds, Matthew J. ; Rice, Julia ; Lavoie, Mitchell W. ; Nipp, Ryan D. ; El-Jawahri, Areej ; Johnson, Patrick Connor Connor</creator><creatorcontrib>Markovitz, Netana H. ; Yi, Alisha ; Odejide, Oreofe O. ; Newcomb, Richard ; Amonoo, Hermioni L. ; Nelson, Ashley M. ; Reynolds, Matthew J. ; Rice, Julia ; Lavoie, Mitchell W. ; Nipp, Ryan D. ; El-Jawahri, Areej ; Johnson, Patrick Connor Connor</creatorcontrib><description>Background: Aggressive non-Hodgkin lymphoma (NHL) commonly affects older adults and is often treated with intensive therapies. Receipt of intensive therapies and absence of a clear transition between the curative and palliative phases of treatment yield prognostic uncertainty and risk for poor end-of-life (EOL) outcomes. However, data regarding the EOL outcomes of this population are lacking. Methods: We conducted a retrospective analysis of adults &gt;65 years with aggressive NHL treated with systemic therapy at Massachusetts General Hospital from 4/2000-7/2020 who subsequently died. We abstracted patient and clinical characteristics and EOL outcomes from the electronic health record (EHR), including patients' place of death, cause of death, palliative care and hospice utilization, and hospice length of stay using the EHR and the Social Security Death Index. We also determined whether patients were hospitalized (yes versus no), received systemic therapy (yes versus no), or were admitted to the ICU (yes versus no) within 30 days of death. Using multivariable logistic regression, we examined factors associated with hospitalization within 30 days of death and hospice utilization. Results: Among 91 patients (median age = 75 years; 37.4% female), the most common lymphoma diagnosis was de novo DLBCL/grade 3B follicular lymphoma (64/91, 70.3%), and the majority (64/91, 70.3%) had advanced stage disease. Overall, 70.3% (64/91) were hospitalized, 34.1% (31/91) received systemic therapy, and 23.3% (21/90) had an intensive care unit admission within 30 days of death. The rates of palliative care consultation and hospice utilization were 47.7% (42/88) and 39.8% (35/88), respectively. A minority (21/88, 23.9%,) received palliative care more than 30 days before death. Of those receiving palliative care consultations, the majority (33/42, 78.6%) occurred exclusively in the inpatient setting, and most (32/42, 76.2%) were seen either as a one-time consultation or followed during a single inpatient hospitalization. Symptom management (24/42, 57.1%) was the most common reason for palliative care consultation, followed by both symptom management and goals of care (11/42, 26.2%) and goals of care (4/42, 9.5%). Only 39.8% (35/88) received hospice services, with 80.7% (71/88) having a hospice length of stay ≤ 7 days. Among hospice enrollees, the median length of stay on hospice was 7 days (range: 0-117). Among all patients, 51.6% (47/91) died in hospital, rehab, or nursing home, 23.1% (21/91) died at home, 11.0% (10/91) died in inpatient hospice or a hospice house, and 14.3% (13/91) had an unknown or other place of death. The most common cause of death was cancer progression (44/91, 48.4%,) followed by infection or cancer treatment complication (20/91, 22.0%). In multivariable analysis, elevated LDH was associated with risk of hospitalization within 30 days of death (OR 3.61, p=0.014). Palliative care consultation (OR 4.45, p=0.005) and hypoalbuminemia (OR 0.29, p=0.026) were associated with likelihood of hospice utilization. Conclusions: Older adults with aggressive NHL often experience high health care utilization and infrequently utilize hospice care at the EOL. Our findings underscore the need for interventions to optimize the quality of EOL care for this population, and provide important data to guide informed decision-making and help inform future interventions aimed at improving the EOL care of this unique geriatric oncology population. No relevant conflicts of interest to declare.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2021-146527</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2021-11, Vol.138 (Supplement 1), p.5005-5005</ispartof><rights>2021 American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S000649712106897X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids></links><search><creatorcontrib>Markovitz, Netana H.</creatorcontrib><creatorcontrib>Yi, Alisha</creatorcontrib><creatorcontrib>Odejide, Oreofe O.</creatorcontrib><creatorcontrib>Newcomb, Richard</creatorcontrib><creatorcontrib>Amonoo, Hermioni L.</creatorcontrib><creatorcontrib>Nelson, Ashley M.</creatorcontrib><creatorcontrib>Reynolds, Matthew J.</creatorcontrib><creatorcontrib>Rice, Julia</creatorcontrib><creatorcontrib>Lavoie, Mitchell W.</creatorcontrib><creatorcontrib>Nipp, Ryan D.</creatorcontrib><creatorcontrib>El-Jawahri, Areej</creatorcontrib><creatorcontrib>Johnson, Patrick Connor Connor</creatorcontrib><title>End-of-Life Care for Older Adults with Aggressive Non-Hodgkin Lymphoma</title><title>Blood</title><description>Background: Aggressive non-Hodgkin lymphoma (NHL) commonly affects older adults and is often treated with intensive therapies. Receipt of intensive therapies and absence of a clear transition between the curative and palliative phases of treatment yield prognostic uncertainty and risk for poor end-of-life (EOL) outcomes. However, data regarding the EOL outcomes of this population are lacking. Methods: We conducted a retrospective analysis of adults &gt;65 years with aggressive NHL treated with systemic therapy at Massachusetts General Hospital from 4/2000-7/2020 who subsequently died. We abstracted patient and clinical characteristics and EOL outcomes from the electronic health record (EHR), including patients' place of death, cause of death, palliative care and hospice utilization, and hospice length of stay using the EHR and the Social Security Death Index. We also determined whether patients were hospitalized (yes versus no), received systemic therapy (yes versus no), or were admitted to the ICU (yes versus no) within 30 days of death. Using multivariable logistic regression, we examined factors associated with hospitalization within 30 days of death and hospice utilization. Results: Among 91 patients (median age = 75 years; 37.4% female), the most common lymphoma diagnosis was de novo DLBCL/grade 3B follicular lymphoma (64/91, 70.3%), and the majority (64/91, 70.3%) had advanced stage disease. Overall, 70.3% (64/91) were hospitalized, 34.1% (31/91) received systemic therapy, and 23.3% (21/90) had an intensive care unit admission within 30 days of death. The rates of palliative care consultation and hospice utilization were 47.7% (42/88) and 39.8% (35/88), respectively. A minority (21/88, 23.9%,) received palliative care more than 30 days before death. Of those receiving palliative care consultations, the majority (33/42, 78.6%) occurred exclusively in the inpatient setting, and most (32/42, 76.2%) were seen either as a one-time consultation or followed during a single inpatient hospitalization. Symptom management (24/42, 57.1%) was the most common reason for palliative care consultation, followed by both symptom management and goals of care (11/42, 26.2%) and goals of care (4/42, 9.5%). Only 39.8% (35/88) received hospice services, with 80.7% (71/88) having a hospice length of stay ≤ 7 days. Among hospice enrollees, the median length of stay on hospice was 7 days (range: 0-117). Among all patients, 51.6% (47/91) died in hospital, rehab, or nursing home, 23.1% (21/91) died at home, 11.0% (10/91) died in inpatient hospice or a hospice house, and 14.3% (13/91) had an unknown or other place of death. The most common cause of death was cancer progression (44/91, 48.4%,) followed by infection or cancer treatment complication (20/91, 22.0%). In multivariable analysis, elevated LDH was associated with risk of hospitalization within 30 days of death (OR 3.61, p=0.014). Palliative care consultation (OR 4.45, p=0.005) and hypoalbuminemia (OR 0.29, p=0.026) were associated with likelihood of hospice utilization. Conclusions: Older adults with aggressive NHL often experience high health care utilization and infrequently utilize hospice care at the EOL. Our findings underscore the need for interventions to optimize the quality of EOL care for this population, and provide important data to guide informed decision-making and help inform future interventions aimed at improving the EOL care of this unique geriatric oncology population. No relevant conflicts of interest to declare.</description><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kM1OAjEURhujiYg-gLu-QPXedjrTiStCQEwmstF1M9MfqA5T0iKGtxfEtatvdb6cHELuER4QFX_s-hgt48CRYVFKXl2QEUquGACHSzICgJIVdYXX5CbnDwAsBJcjMp8NlkXPmuAdnbbJUR8TXfbWJTqxX_0u0--wW9PJapVczmHv6Gsc2CLa1WcYaHPYbNdx096SK9_22d397Zi8z2dv0wVrls8v00nDDIqqOgoYUYKDrrC2kl5IV1ola6WQd9AKZWqHlZemQigMVyBU6WtZCOxE6VtViDHB869JMefkvN6msGnTQSPoUwj9G0KfQuhziCPzdGbcUWwfXNLZBDcYZ0NyZqdtDP_QPy0eZCM</recordid><startdate>20211123</startdate><enddate>20211123</enddate><creator>Markovitz, Netana H.</creator><creator>Yi, Alisha</creator><creator>Odejide, Oreofe O.</creator><creator>Newcomb, Richard</creator><creator>Amonoo, Hermioni L.</creator><creator>Nelson, Ashley M.</creator><creator>Reynolds, Matthew J.</creator><creator>Rice, Julia</creator><creator>Lavoie, Mitchell W.</creator><creator>Nipp, Ryan D.</creator><creator>El-Jawahri, Areej</creator><creator>Johnson, Patrick Connor Connor</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20211123</creationdate><title>End-of-Life Care for Older Adults with Aggressive Non-Hodgkin Lymphoma</title><author>Markovitz, Netana H. ; Yi, Alisha ; Odejide, Oreofe O. ; Newcomb, Richard ; Amonoo, Hermioni L. ; Nelson, Ashley M. ; Reynolds, Matthew J. ; Rice, Julia ; Lavoie, Mitchell W. ; Nipp, Ryan D. ; El-Jawahri, Areej ; Johnson, Patrick Connor Connor</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1377-49c360e0b4dd75f35e6d8598812b0a38c9e17f5c7104c280386f95431b36fa843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Markovitz, Netana H.</creatorcontrib><creatorcontrib>Yi, Alisha</creatorcontrib><creatorcontrib>Odejide, Oreofe O.</creatorcontrib><creatorcontrib>Newcomb, Richard</creatorcontrib><creatorcontrib>Amonoo, Hermioni L.</creatorcontrib><creatorcontrib>Nelson, Ashley M.</creatorcontrib><creatorcontrib>Reynolds, Matthew J.</creatorcontrib><creatorcontrib>Rice, Julia</creatorcontrib><creatorcontrib>Lavoie, Mitchell W.</creatorcontrib><creatorcontrib>Nipp, Ryan D.</creatorcontrib><creatorcontrib>El-Jawahri, Areej</creatorcontrib><creatorcontrib>Johnson, Patrick Connor Connor</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Markovitz, Netana H.</au><au>Yi, Alisha</au><au>Odejide, Oreofe O.</au><au>Newcomb, Richard</au><au>Amonoo, Hermioni L.</au><au>Nelson, Ashley M.</au><au>Reynolds, Matthew J.</au><au>Rice, Julia</au><au>Lavoie, Mitchell W.</au><au>Nipp, Ryan D.</au><au>El-Jawahri, Areej</au><au>Johnson, Patrick Connor Connor</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>End-of-Life Care for Older Adults with Aggressive Non-Hodgkin Lymphoma</atitle><jtitle>Blood</jtitle><date>2021-11-23</date><risdate>2021</risdate><volume>138</volume><issue>Supplement 1</issue><spage>5005</spage><epage>5005</epage><pages>5005-5005</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Background: Aggressive non-Hodgkin lymphoma (NHL) commonly affects older adults and is often treated with intensive therapies. Receipt of intensive therapies and absence of a clear transition between the curative and palliative phases of treatment yield prognostic uncertainty and risk for poor end-of-life (EOL) outcomes. However, data regarding the EOL outcomes of this population are lacking. Methods: We conducted a retrospective analysis of adults &gt;65 years with aggressive NHL treated with systemic therapy at Massachusetts General Hospital from 4/2000-7/2020 who subsequently died. We abstracted patient and clinical characteristics and EOL outcomes from the electronic health record (EHR), including patients' place of death, cause of death, palliative care and hospice utilization, and hospice length of stay using the EHR and the Social Security Death Index. We also determined whether patients were hospitalized (yes versus no), received systemic therapy (yes versus no), or were admitted to the ICU (yes versus no) within 30 days of death. Using multivariable logistic regression, we examined factors associated with hospitalization within 30 days of death and hospice utilization. Results: Among 91 patients (median age = 75 years; 37.4% female), the most common lymphoma diagnosis was de novo DLBCL/grade 3B follicular lymphoma (64/91, 70.3%), and the majority (64/91, 70.3%) had advanced stage disease. Overall, 70.3% (64/91) were hospitalized, 34.1% (31/91) received systemic therapy, and 23.3% (21/90) had an intensive care unit admission within 30 days of death. The rates of palliative care consultation and hospice utilization were 47.7% (42/88) and 39.8% (35/88), respectively. A minority (21/88, 23.9%,) received palliative care more than 30 days before death. Of those receiving palliative care consultations, the majority (33/42, 78.6%) occurred exclusively in the inpatient setting, and most (32/42, 76.2%) were seen either as a one-time consultation or followed during a single inpatient hospitalization. Symptom management (24/42, 57.1%) was the most common reason for palliative care consultation, followed by both symptom management and goals of care (11/42, 26.2%) and goals of care (4/42, 9.5%). Only 39.8% (35/88) received hospice services, with 80.7% (71/88) having a hospice length of stay ≤ 7 days. Among hospice enrollees, the median length of stay on hospice was 7 days (range: 0-117). Among all patients, 51.6% (47/91) died in hospital, rehab, or nursing home, 23.1% (21/91) died at home, 11.0% (10/91) died in inpatient hospice or a hospice house, and 14.3% (13/91) had an unknown or other place of death. The most common cause of death was cancer progression (44/91, 48.4%,) followed by infection or cancer treatment complication (20/91, 22.0%). In multivariable analysis, elevated LDH was associated with risk of hospitalization within 30 days of death (OR 3.61, p=0.014). Palliative care consultation (OR 4.45, p=0.005) and hypoalbuminemia (OR 0.29, p=0.026) were associated with likelihood of hospice utilization. Conclusions: Older adults with aggressive NHL often experience high health care utilization and infrequently utilize hospice care at the EOL. Our findings underscore the need for interventions to optimize the quality of EOL care for this population, and provide important data to guide informed decision-making and help inform future interventions aimed at improving the EOL care of this unique geriatric oncology population. No relevant conflicts of interest to declare.</abstract><pub>Elsevier Inc</pub><doi>10.1182/blood-2021-146527</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2021-11, Vol.138 (Supplement 1), p.5005-5005
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2021_146527
source ScienceDirect Additional Titles
title End-of-Life Care for Older Adults with Aggressive Non-Hodgkin Lymphoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T22%3A04%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=End-of-Life%20Care%20for%20Older%20Adults%20with%20Aggressive%20Non-Hodgkin%20Lymphoma&rft.jtitle=Blood&rft.au=Markovitz,%20Netana%20H.&rft.date=2021-11-23&rft.volume=138&rft.issue=Supplement%201&rft.spage=5005&rft.epage=5005&rft.pages=5005-5005&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2021-146527&rft_dat=%3Celsevier_cross%3ES000649712106897X%3C/elsevier_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1377-49c360e0b4dd75f35e6d8598812b0a38c9e17f5c7104c280386f95431b36fa843%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true